US › Healthcare

Cullinan Oncology LLC (CGEM)

US · Healthcare · Biotechnology

$17.55+8.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-49.7M
Profit YoY
-2.4%
EPS
$-0.75
EPS estimate
$-0.84

EPS came in at -0.75 against a street estimate of -0.84 — a beat of 10.7%.

Key statistics

Market cap
$1.01B
Forward P/E
6.7
P/B
2.77
Book value
$5.96
EPS (TTM)
$-3.37
52-week high
$19.43
52-week low
$5.68
50-day MA
$16.30
200-day MA
$13.05
Beta
-0.02

Analyst view

Analysts rate Cullinan Oncology LLC a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $31.64.

Shareholding

Insiders
0.45%
Institutions
107.81%

Largest institutional holders

FundStake
Lynx1 Capital Management, LP14.58%
MPM Oncology Impact Management LP12.44%
Bvf Inc9.36%
BlackRock Inc7.24%
Kynam Capital Management, LP5.07%
State Street Corp4.14%
Vanguard Capital Management, LLC4.04%
T. Rowe Price Associates, Inc.3.30%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cullinan Oncology LLC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.